Perturbation biology models predict c-Myc as an effective co-target in RAF inhibitor resistant melanoma cells
Anil KorkutiD, Weiqing Wang, Emek DemiriD, Bülent Arman AksoyiD, Xiaohong Jing, Evan Molinelli, Özgün BaburiD, Debra Bemis, David B. SolitiD, Christine Pratilas, Chris SanderiD
Abstract
Systematic prediction of cellular response to perturbations is a central challenge in biology, both for mechanistic explanations and for the design of effective therapeutic interventions. We addressed this challenge using a computational/experimental method, termed perturbation biology, which combines high-throughput (phospho)proteomic and phenotypic response profiles to targeted perturbations, prior information from signaling databases and network inference algorithms from statistical physics. The resulting network models are computationally executed to predict the effects of tens of thousands of untested perturbations. We report cell type-specific network models of signaling in RAF-inhibitor resistant melanoma cells based on data from 89 combinatorial perturbation conditions and 143 readouts per condition. Quantitative simulations predicted c-Myc as an effective co-target with BRAF or MEK. Experiments showed that co-targeting c-Myc, using the BET bromodomain inhibitor JQ1, and the RAF/MEK pathway, using kinase inhibitors is both effective and synergistic in this context. We propose these combinations as pre-clinical candidates to prevent or overcome RAF inhibitor resistance in melanoma.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- BRAF inhibitor resistance confers increased sensitivity to mitotic inhibitors
S. Misek, T. Dexheimer, … K. A. Gallo·bioRxiv·Apr 15, 2021
- Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma
Helma Zecena, Daniel Myklatun Tveit, … Fabian V. Filipp·BMC Systems BiologyPeer-reviewed·Apr 3, 2018
- The dynamics of ERK signaling in melanoma, and the response to BRAF or MEK inhibition, are cell cycle dependent.
Chloe M. Simpson, Nicola Ferrari, … Chris Bakal·bioRxiv·Aug 13, 2018
- Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma
Andrew Goetz, Frances Shanahan, … Luca Gerosa·CancersPeer-reviewed·Aug 22, 2024
- Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade
Bardees M. Foda, Sean A. Misek, … Richard R. Neubig·International Journal of CancerPeer-reviewed·Jun 19, 2024
- Quantifying ERK-activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling
S. Hamis, Y. Kapelyukh, … M. A. J. Chaplain·British Journal of CancerPeer-reviewed·Oct 7, 2021